Understanding the Link Between Antidepressants and Dry Eye
Antidepressants are among the most commonly prescribed medications in the United States. While they play a vital role in managing depression, anxiety, and other mental health conditions, they can also produce side effects that extend beyond mood and energy levels. One of the most frequently overlooked side effects is dry eye disease, a condition that develops when your eyes do not produce enough tears or when the tears evaporate too quickly to keep the eye surface healthy.
The TFOS DEWS III report, a major international review of dry eye research, identifies systemic medications as a significant and often underrecognized lifestyle factor contributing to dry eye disease. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants, are among the medication classes most strongly associated with this condition.
Many antidepressants have what are called anticholinergic properties. To understand what this means, it helps to know a little about how your body produces tears. Your lacrimal glands (the small glands located above each eye responsible for making the watery part of your tears) are controlled by parasympathetic nerve signals. These signals tell the glands when and how much fluid to release.
Anticholinergic medications block these parasympathetic nerve receptors. When the receptors are blocked, the biological signal that tells your lacrimal glands to secrete the watery (aqueous) layer of the tear film is disrupted. The result is a noticeable drop in overall tear volume. This type of dry eye is called aqueous-deficient dry eye because the problem stems from not having enough of the watery component that makes up the bulk of your tears.
Not all antidepressants affect the eyes in the same way or to the same degree. Tricyclic antidepressants tend to have the strongest anticholinergic effects, which means they are more likely to cause a significant reduction in tear production. SSRIs also carry a meaningful risk, though their anticholinergic activity is generally milder. Other classes, including serotonin-norepinephrine reuptake inhibitors (SNRIs), may also contribute to dry eye symptoms in some patients.
It is important to understand that the risk of developing dry eye depends on multiple factors, including the specific medication, the dosage, how long you have been taking it, and your individual body chemistry. Not everyone on antidepressants will develop dry eye, but awareness of the connection can help you catch symptoms early.
When your lacrimal glands produce less fluid, the remaining tears become more concentrated. Researchers measure this using a test called tear osmolarity, which assesses the salt concentration in your tears. Clinical literature reviewed in the TFOS DEWS III framework shows that patients on long-term antidepressant therapy tend to have higher tear osmolarity than patients not taking these medications.
This increase in salt concentration creates what scientists call a hyperosmolar environment on the surface of your eye. In simpler terms, the tears become too salty. This triggers a chain reaction of cellular stress and chronic inflammation on the eye's surface. Over time, this inflammation can damage the delicate cells of the cornea (the clear front window of the eye) and the conjunctiva (the thin tissue lining the inside of the eyelids and covering the white of the eye), making dry eye symptoms progressively worse.
Eye care professionals use a test called the Schirmer's test to measure how much fluid your lacrimal glands produce. During this simple, painless test, a small strip of filter paper is placed along the inside of the lower eyelid. After a few minutes, the amount of moisture absorbed by the paper is measured. Research reviewed in the TFOS DEWS III report demonstrates that patients on long-term antidepressant therapy have noticeably lower Schirmer's test scores compared to patients not taking these medications.
Lower Schirmer's scores confirm that the eyes are producing less of the watery tear layer. Combined with higher tear osmolarity readings, these test results paint a clear picture of how antidepressants can shift the balance of the tear film and lead to ongoing dry eye symptoms.
One of the challenges of antidepressant-related dry eye is that it can create a self-reinforcing cycle. Reduced tear production leads to higher osmolarity, which triggers inflammation. Inflammation then damages the cells that help produce and maintain a healthy tear film, which further reduces tear quality and quantity. Without intervention, this cycle can gradually worsen, making it important to address dry eye symptoms early rather than waiting for them to become severe.
Who Is Most at Risk for Antidepressant-Related Dry Eye
The longer you take an antidepressant, the more sustained the impact on your tear-producing glands becomes. Patients who have been on antidepressant medication for months or years are more likely to develop clinically significant dry eye compared to those who take the medication for shorter periods. If you have been on antidepressant therapy for an extended time and notice eye discomfort, it is worth discussing this with your eye care provider.
Anticholinergic effects can add up when you are taking more than one medication that blocks parasympathetic nerve signals. Some allergy medications, bladder medications, and sleep aids also have anticholinergic properties. When combined with an antidepressant, the total anticholinergic load on your body increases, which can lead to more pronounced dry eye symptoms. Sharing your full medication list with your eye care provider helps them assess your overall risk.
Tear production naturally decreases with age. When this age-related decline is combined with the anticholinergic effects of an antidepressant, the resulting drop in tear volume can be significant. Older adults are also more likely to take multiple medications, which further increases the risk of cumulative anticholinergic effects on the eyes.
Women are at higher risk for dry eye disease in general, partly due to hormonal changes associated with menopause and other life stages. When antidepressant use is added to this existing risk factor, the likelihood of developing noticeable dry eye symptoms increases. Women who take antidepressants should be especially mindful of changes in eye comfort and report them to their eye care provider.
Contact lenses depend on a healthy, well-hydrated tear film to stay comfortable on the eye. When antidepressants reduce tear volume, the lens surface can dry out more quickly, leading to irritation, blurred vision, and a gritty feeling. Patients who wear contacts and take antidepressants may need to adjust their lens care routine, use additional lubricating drops, or discuss alternative lens options with their eye care provider.
Environmental factors play a significant role in dry eye severity. Air conditioning, forced-air heating, low humidity, and windy conditions all accelerate tear evaporation. When your body is already producing fewer tears due to antidepressant use, these environmental stressors can push your eyes past the tipping point from mild dryness to persistent discomfort.
What to Expect When Managing Antidepressant-Related Dry Eye
This point is essential. You should not stop taking or reduce the dose of any antidepressant without consulting the physician who prescribed it. Abruptly discontinuing antidepressants can cause serious withdrawal symptoms and a return of the condition being treated. The TFOS DEWS III management guidelines emphasize that dry eye symptoms caused by antidepressants should be managed alongside the medication, not by stopping it. Your mental health is a priority, and effective strategies exist to manage your eye comfort without compromising your psychiatric care.
Preservative-free artificial tears are typically the first line of relief for antidepressant-related dry eye. The TFOS DEWS III algorithm specifically recommends osmoprotective artificial tears for this type of dry eye. Osmoprotective drops are formulated to counteract the high salt concentration in your tears by restoring a healthier osmotic balance on the eye surface. This helps protect the delicate surface cells from the damaging effects of hyperosmolarity.
Using these drops frequently throughout the day, rather than only when symptoms feel severe, helps maintain a more consistent level of moisture and reduces the cumulative stress on the eye surface. Your eye care provider can recommend a specific product and schedule based on the severity of your symptoms.
When artificial tears alone are not providing enough relief, punctal plugs offer an effective next step. Punctal plugs are tiny, painless devices that are placed in the puncta (the small drainage openings located at the inner corners of your upper and lower eyelids). Normally, tears drain through these openings and into the nasal passages. By gently blocking this drainage pathway, punctal plugs help your natural tears and any supplemental drops stay on the eye surface longer.
This is especially helpful for antidepressant-related dry eye because the core problem is insufficient tear volume. Rather than trying to replace all of the missing fluid with drops, punctal plugs make the most of the tears your eyes are still producing. The procedure to place them is quick, performed in the office, and most patients do not feel the plugs once they are in place.
Simple changes to your environment can meaningfully improve dry eye comfort. Using a humidifier in your home or office adds moisture to the air and slows tear evaporation. Positioning your computer screen slightly below eye level encourages a more natural, partially closed eyelid position that reduces the exposed surface area of the eye. Avoiding direct airflow from fans, vents, or car heaters on your face also helps preserve your tear film.
Taking regular breaks during extended reading or screen time is another effective strategy. The 20-20-20 rule is a simple guideline: every 20 minutes, look at something 20 feet away for 20 seconds. This encourages blinking and gives your tear film a chance to refresh.
Regular comprehensive eye exams are important for anyone managing medication-related dry eye. At Washington Eye Institute, our multidisciplinary ophthalmology and optometry team evaluates not just your vision but also the health of your tear film, the function of your meibomian glands, and the condition of your eye surface. These detailed assessments help track changes over time and allow your care team to adjust your management plan as needed.
Sharing your complete medication list with your eye care provider at each visit ensures they have the full picture. If your antidepressant dosage changes or if you start or stop other medications with anticholinergic effects, your dry eye management plan may need to be updated accordingly.
For patients whose dry eye symptoms remain bothersome despite artificial tears, punctal plugs, and environmental changes, additional therapies may be considered. Intense Pulsed Light (IPL) therapy is a gentle, light-based treatment that reduces inflammation along the eyelid margins. While IPL is most commonly associated with evaporative dry eye, it can also benefit patients with mixed dry eye presentations where inflammation is a significant contributor.
Your eye care provider will work with you to determine the most appropriate combination of treatments based on your specific type and severity of dry eye. The goal is to find a management plan that keeps your eyes comfortable while you continue the medications that support your mental health.
Frequently Asked Questions
Some antidepressants have stronger anticholinergic effects than others, so switching medications could potentially reduce dry eye symptoms. However, any change to your psychiatric medication should only be made by your prescribing physician, who will weigh the benefits and risks for your mental health. If dry eye is a concern, your eye care provider can communicate with your prescribing physician to explore options together.
Dry eye symptoms can develop at different times depending on the medication, dosage, and individual factors. Some patients notice dryness within the first few weeks of starting a new antidepressant, while others may not develop symptoms until months into treatment. Paying attention to changes in eye comfort from the start of any new medication helps you catch symptoms early and begin management promptly.
In many cases, tear production can improve after discontinuing a medication with anticholinergic effects, as the nerve signals to the lacrimal glands are no longer being blocked. However, recovery time varies, and some patients may have developed secondary changes such as chronic inflammation that require continued management. Any decision to stop an antidepressant should be guided by your prescribing physician.
Preservative-free artificial tears available over the counter can provide meaningful relief for mild to moderate symptoms. For more significant dry eye, additional interventions such as osmoprotective drops, punctal plugs, or in-office treatments may be needed. Your eye care provider can help you determine the right level of care based on the results of your eye exam.
Some antidepressants have been associated with other ocular effects, including blurred vision and changes in pupil size, both of which are related to their anticholinergic activity. If you experience any visual changes while taking an antidepressant, it is important to have a comprehensive eye exam to determine the cause and rule out other conditions.
Yes. Scheduling a comprehensive eye exam before starting an antidepressant gives your eye care provider a baseline measurement of your tear production and overall eye surface health. This baseline makes it much easier to detect changes during treatment. Starting a routine of preservative-free artificial tears and making environmental adjustments such as using a humidifier can also help prepare your eyes for potential changes in tear production.